American Society of Hematology

ASH Meeting on Hematologic Malignancies

Early registration is now open. Hear top experts in hematologic malignancies discuss the latest developments in clinical care.

Learn more

Upcoming Webinar

Register for ASH's upcoming webinar, Chimeric T-Cell Antigen Receptor Therapy in Leukemia and Lymphoma, taking place April 22.

Learn more

CME Credit and Certificate of Attendance

Obtain CME credit and a certificate of attendance for the 56th ASH Annual Meeting by April 17, 2015.

Learn more

Protect Medical Research

Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
  • Statement from ASH President David A. Williams, MD, on Passage of Senate Bill to Repeal Sustainable Growth Rate

    Last night the Senate passed legislation permanently repealing the Sustainable Growth Rate, a flawed formula mandating annual reductions in Medicare physician payments, and replacing it with a 0.5 percent annual physician pay increase for the next five years.

  • American Society of Hematology Provides ‘Bridge Funding’ for Critical Blood Disease Research

    The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the latest recipients of the ASH Bridge Grant Awards. These one-year, $150,000 awards are designed to provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the NIH due to severe funding reductions. The 11 ASH Bridge Grant recipients announced today join 51 hematologists that have received funding since ASH committed $9 million in Society funds to create the program in 2012.

  • Study: Gene Therapy Superior to Half-Matched Transplant for Children with “Bubble Boy Disease”

    New research published online today in Blood, the Journal of the American Society of Hematology, reports that children with “bubble boy disease” who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder – also known as X-linked severe combined immunodeficiency (SCID-X1) – receiving the two therapeutic approaches.

  • Experts Set Strategic Priorities for Lymphoma Research

    A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma.

View all press releases
  • SGR Fix Becomes Law

    On April 16, President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) into law.  Follow the link above to read a detailed report of what the legislation means for hematologists.

  • NIH Seeks Information on Optimizing Funding Policies and Other Strategies to Improve the Impact and Sustainability of Biomedical Research

    The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise.  ASH members are encouraged to submit comments in response to this request.

  • CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy

    On March 30, the Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare Part B and Part D payment for biosimilars that are relevant to hematology.  On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.), as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic therapy.  Some of the most important regimens for the treatment of patients with hematologic disorders are biologic, so the release of this information is helpful for the field.

  • IOM National Cancer Policy Forum Releases a Report on Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies

    The Institute of Medicine National Cancer Policy Forum (IOM NCPF) has released a summary report on a workshop it hosted on November 10, 2014, titled "Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies."  This report highlights the numerous challenges raised by workshop participants on the development of biomarker tests, implementation of cancer therapies into the clinic, clinical trial structure and reimbursement issues related to molecular profiling tests.

View all policy news
View all Hematologist articles